Facebook Linkedin RSS Twitter Youtube
Home 2015

Ventana Medical Systems

Halozyme, Roche’s Ventana to Co-Develop Companion Diagnostic
Cancer

Halozyme, Roche’s Ventana to Co-Develop Companion Diagnostic

Ventana Licenses BRAF V600E Mutation Antibody for Diagnostic Purposes
Cancer

Ventana Licenses BRAF V600E Mutation Antibody for Diagnostic Purposes

Illumina Institutes Poison Pill to Ward Off Roche’s $5.7B Purchase Proposal
Industry News

Illumina Institutes Poison Pill to Ward Off Roche’s $5.7B Purchase Proposal

Ventana Joins Pfizer, CST in Developing Companion Dx for Personalized Cancer Treatment
Cancer

Ventana Joins Pfizer, CST in Developing Companion Dx for Personalized Cancer Treatment

Aeterna Zentaris Taps Ventana for Companion Diagnostic to LHRH-Receptor Targeting Drug
Cancer

Aeterna Zentaris Taps Ventana for Companion Diagnostic to LHRH-Receptor Targeting Drug

Ventana, Advanced Cell Diagnostics Ally for Automated RNA In Situ Hybridization Assays
Bioprocessing

Ventana, Advanced Cell Diagnostics Ally for Automated RNA In Situ Hybridization Assays

FDA Clears Roche’s Fully Automated Her2 Gene Status Diagnostic Assay
Cancer

FDA Clears Roche’s Fully Automated Her2 Gene Status Diagnostic Assay

Ventana Licenses Cell Signaling’s EGFR IP and Antibodies for Tissue-Based IVDs
Cancer

Ventana Licenses Cell Signaling’s EGFR IP and Antibodies for Tissue-Based IVDs

Ventana to Work on Companion Diagnostic for Clovis’ Phase II Lipid-Conjugated Gemcitabine
Cancer

Ventana to Work on Companion Diagnostic for Clovis’ Phase II Lipid-Conjugated Gemcitabine

Ventana Says Its Is Worth More Than $3B
Insights

Ventana Says Its Is Worth More Than $3B

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.